Clinical trial
Long-Term Assessment of Safety and Therapeutic Benefit of Viaskin® Peanut Epicutaneous Treatment in Peanut-Allergic Children: A 6-Month Randomized, Double-Blind, Placebo-Controlled Phase III Study Followed by an Open-Label Active Treatment (REALISE Study)
NCT02916446 is registered in ClinicalTrials.gov with DBV Technologies as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Long-Term Assessment of Safety and Therapeutic Benefit of Viaskin® Peanut Epicutaneous Treatment in Peanut-Allergic Children: A 6-Month Randomized, Double-Blind, Placebo-Controlled Phase III Study Followed by an Open-Label Active Treatment (REALISE Study)
- Lead sponsor
- DBV Technologies
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- October 25, 2016
- Completion date
- October 7, 2020
- Enrollment
- 393 (actual)
- Sites
- 32
Conditions
As the registry lists them; a condition with its own page is linked.
peanut allergy